Key non-cancer indications for BCR-ABL inhibitors include neurodegenerative diseases, with Alzheimer’s and Parkinson’s diseases frequently being associated, particularly for nilotinib and dasatinib, which have shown preclinical and clinical neuroprotective effects. The gene discussed is ABL1; the disease is cancer.